Impact of aldosterone on osteoinductive signaling and vascular calcification

Nephron - Physiology

Volumn 128, Issue 1-2, 2014, Pages 40-45

  Lang, Florian ^a   Ritz, Eberhard ^b   Alesutan, Ioana ^a   Voelkl, Jakob ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Aldosterone; Chronic kidney disease; Klotho; Mineralocorticoid receptor; Osteoinductive signaling; PIT1; Spironolactone

Indexed keywords

ALDOSTERONE; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; MINERALOCORTICOID; MINERALOCORTICOID RECEPTOR; PHOSPHATE; PHOSPHATE TRANSPORTER; TRANSCRIPTION FACTOR PIT 1; MINERALOCORTICOID ANTAGONIST; SLC20A1 PROTEIN, HUMAN; SODIUM PHOSPHATE COTRANSPORTER 3; SPIRONOLACTONE;

BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR RISK; CARTILAGE CELL; CHRONIC KIDNEY DISEASE; HUMAN; HYPERALDOSTERONISM; HYPERPHOSPHATEMIA; NONHUMAN; NUCLEAR REPROGRAMMING; OSTEOBLAST; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE CELL; VASCULAR TISSUE; ANIMAL; CARDIOVASCULAR DISEASES; CHRONIC KIDNEY FAILURE; COMPLICATION; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR CALCIFICATION; VASCULAR SMOOTH MUSCLE;

ALDOSTERONE; ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; HYPERPHOSPHATEMIA; MICE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MUSCLE, SMOOTH, VASCULAR; RENAL INSUFFICIENCY, CHRONIC; SIGNAL TRANSDUCTION; SODIUM-PHOSPHATE COTRANSPORTER PROTEINS, TYPE III; SPIRONOLACTONE; VASCULAR CALCIFICATION;

EID: 84928345747     PISSN: None     EISSN: 16602137     Source Type: Journal    
DOI: 10.1159/000368268     Document Type: Review

References (103)

1. Greenwald SE: Ageing of the conduit arteries. J Pathol 2007; 211: 157-172.
2. An WS, Lee SM, Park TH, Kim SE, Kim KH, Park YJ, Son YK: Association between diastolic dysfunction by color tissue Doppler imaging and vascular calcification on plain radiographs in dialysis patients. Kidney Blood Press Res 2012; 35: 619-626.
3. Hofmann Bowman MA, McNally EM: Genetic pathways of vascular calcification. Trends Cardiovasc Med 2012; 22: 93-98.
4. Ikee R, Tsunoda M, Sasaki N, Sato N, Hashimoto N: Emerging effects of sevelamer in chronic kidney disease. Kidney Blood Press Res 2013; 37: 24-32.
5. Johnson RC, Leopold JA, Loscalzo J: Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res 2006; 99: 1044-1059.
6. Lang F, Ritz E, Voelkl J, Alesutan I: Vascular calcification-is aldosterone a culprit? Nephrol Dial Transplant 2013; 28: 1080-1084.
7. Lee SY, Kim HY, Gu SW, Kim HJ, Yang DH: 25-Hydroxyvitamin D levels and vascular calcification in predialysis and dialysis patients with chronic kidney disease. Kidney Blood Press Res 2012; 35: 349-354.
8. Lucisano S, Buemi M, Passantino A, Aloisi C, Cernaro V, Santoro D: New insights on the role of vitamin D in the progression of renal damage. Kidney Blood Press Res 2013; 37: 667-678.
9. Shih CJ, Tarng DC, Yang WC, Yang CY: Parathyroidectomy reduces intradialytic hypotension in hemodialysis patients with secondary hyperparathyroidism. Kidney Blood Press Res 2013; 37: 323-331.
10. Staude H, Jeske S, Schmitz K, Warncke G, Fischer DC: Cardiovascular risk and mineral bone disorder in patients with chronic kidney disease. Kidney Blood Press Res 2013; 37: 68-83.
11. Sun Y, Byon C, Yuan K, Chen J, Mao X, Heath JM, Javed A, Zhang K, Anderson PG, Chen Y: Smooth muscle cell-specific runx2 deficiency inhibits vascular calcification. Circ Res 2012; 111: 543-552.
12. Wang C, Jiang L, Feng S, Shi Y, Shen H, Shi X, Wang Z, Zeng Y: Risk factor analysis of calcification in aortic and mitral valves in maintenance peritoneal dialysis patients. Kidney Blood Press Res 2013; 37: 488-495.
13. Wu M, Rementer C, Giachelli CM: Vascular calcification: an update on mechanisms and challenges in treatment. Calcif Tissue Int 2013; 93: 365-373.
14. Yilmaz M, Unsal A, Oztekin E, Kesmezacar O, Kaptanogullari OH, Eren N: The prevalence of hypertension, valve calcification and left ventricular hypertrophy and geometry in peritoneal dialysis patients. Kidney Blood Press Res 2012; 35: 431-437.
15. London GM: Bone-vascular cross-talk. J Nephrol 2012; 25: 619-625.
16. Herrmann M, Kinkeldey A, Jahnen-Dechent W: Fetuin-A function in systemic mineral metabolism. Trends Cardiovasc Med 2012; 22: 197-201.
17. Lu X, Gao B, Yasui T, Li Y, Liu T, Mao X, Hirose M, Wu Y, Yu D, Zhu Q, Kohri K, Xiao C: Matrix Gla protein is involved in crystal formation in kidney of hyperoxaluric rats. Kidney Blood Press Res 2013; 37: 15-23.
18. Shroff RC, McNair R, Figg N, Skepper JN, Schurgers L, Gupta A, Hiorns M, Donald AE, Deanfield J, Rees L, Shanahan CM: Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 2008; 118: 1748-1757.
19. Shroff R, Long DA, Shanahan C: Mechanistic insights into vascular calcification in CKD. J Am Soc Nephrol 2013; 24: 179-189.
20. Al Aly Z: Vascular calcification in uremia: what is new and where are we going? Adv Chronic Kidney Dis 2008; 15: 413-419.
21. Ellam TJ, Chico TJ: Phosphate: the new cholesterol? The role of the phosphate axis in non-uremic vascular disease. Atherosclerosis 2012; 220: 310-318.
22. Giachelli CM: The emerging role of phosphate in vascular calcification. Kidney Int 2009; 75: 890-897.
23. Hu MC, Shi M, Zhang J, Quinones H, Griffith C, Kuro-o M, Moe OW: Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011; 22: 124-136.
24. Kanno Y, Into T, Lowenstein CJ, Matsushita K: Nitric oxide regulates vascular calcification by interfering with TGF-signalling. Cardiovasc Res 2008; 77: 221-230.
25. Kuro-o M: Klotho in health and disease. Curr Opin Nephrol Hypertens 2012; 21: 362-368.
26. Lau WL, Leaf EM, Hu MC, Takeno MM, Kuroo M, Moe OW, Giachelli CM: Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int 2012; 82: 1261-1270.
27. Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, Aebersold R, Schinke T, Karsenty G, Giachelli CM: Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001; 89: 1147-1154.
28. Torres PA, De Broe M: Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease. Kidney Int 2012; 82: 19-25.
29. Voelkl J, Alesutan I, Leibrock CB, Quintanilla-Martinez L, Kuhn V, Feger M, Mia S, Ahmed MS, Rosenblatt KP, Kuro O, Lang F: Spironolactone ameliorates PIT1-dependent vascular osteoinduction in klotho-hypomorphic mice. J Clin Invest 2013; 123: 812-822.
30. Li X, Yang HY, Giachelli CM: Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 2006; 98: 905-912.
31. Villa-Bellosta R, Levi M, Sorribas V: Vascular smooth muscle cell calcification and SLC20 inorganic phosphate transporters: effects of PDGF, TNF-?, and Pi. Pflugers Arch 2009; 458: 1151-1161.
32. Crouthamel MH, Lau WL, Leaf EM, Chavkin NW, Wallingford MC, Peterson DF, Li X, Liu Y, Chin MT, Levi M, Giachelli CM: Sodiumdependent phosphate cotransporters and phosphate-induced calcification of vascular smooth muscle cells: redundant roles for PiT-1 and PiT-2. Arterioscler Thromb Vasc Biol 2013; 33: 2625-2632.
33. Lee HL, Woo KM, Ryoo HM, Baek JH: Tumor necrosis factor-? increases alkaline phosphatase expression in vascular smooth muscle cells via MSX2 induction. Biochem Biophys Res Commun 2010; 391: 1087-1092.
34. Shao JS, Cheng SL, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, Towler DA: Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest 2005; 115: 1210-1220.
35. O'Neill WC, Sigrist MK, McIntyre CW: Plasma pyrophosphate and vascular calcification in chronic kidney disease. Nephrol Dial Transplant 2010; 25: 187-191.
36. Kuro-o M: Phosphate and klotho. Kidney Int Suppl 2011;S20-S23.
37. Hu MC, Kuro O, Moe OW: The emerging role of klotho in clinical nephrology. Nephrol Dial Transplant 2012; 27: 2650-2657.
38. Fischer SS, Kempe DS, Leibrock CB, Rexhepaj R, Siraskar B, Boini KM, Ackermann TF, Foller M, Hocher B, Rosenblatt KP, Kuro-o M, Lang F: Hyperaldosteronism in klotho-deficient mice. Am J Physiol Renal Physiol 2010; 299:F1171-F1177.
39. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45-51.
40. Ellam T, Hameed A, Ul Haque R, Muthana M, Wilkie M, Francis SE, Chico TJ: Vitamin D deficiency and exogenous vitamin D excess similarly increase diffuse atherosclerotic calcification in apolipoprotein E knockout mice. PLoS One 2014; 9:e88767.
41. Alesutan I, Feger M, Pakladok T, Mia S, Ahmed MS, Voelkl J, Lang F: 25-Hydroxyvitamin D 3 1?-hydroxylase-dependent stimulation of renal klotho expression by spironolactone. Kidney Blood Press Res 2013; 37: 475-487.
42. Lim K, Lu TS, Molostvov G, Lee C, Lam FT, Zehnder D, Hsiao LL: Vascular klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation 2012; 125: 2243-2255.
43. Shalhoub V, Shatzen EM, Ward SC, Davis J, Stevens J, Bi V, Renshaw L, Hawkins N, Wang W, Chen C, Tsai MM, Cattley RC, Wronski TJ, Xia X, Li X, Henley C, Eschenberg M, Richards WG: FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 2012; 122: 2543-2553.
44. Fang Y, Ginsberg C, Seifert M, Agapova O, Sugatani T, Register TC, Freedman BI, Monier-Faugere MC, Malluche H, Hruska KA: CKD-induced wingless/integration-1 inhibitors and phosphorus cause the CKD-mineral and bone disorder. J Am Soc Nephrol 2014; 25: 1760-1773.
45. Jimbo R, Kawakami-Mori F, Mu S, Hirohama D, Majtan B, Shimizu Y, Yatomi Y, Fukumoto S, Fujita T, Shimosawa T: Fibroblast growth factor-23 accelerates phosphate-induced vascular calcification in the absence of klotho deficiency. Kidney Int 2014; 85: 1103-1111.
46. Lindberg K, Olauson H, Amin R, Ponnusamy A, Goetz R, Taylor RF, Mohammadi M, Canfield A, Kublickiene K, Larsson TE: Arterial klotho expression and FGF23 effects on vascular calcification and function. PLoS One 2013; 8:e60658.
47. Scialla JJ, Lau WL, Reilly MP, Isakova T, Yang HY, Crouthamel MH, Chavkin NW, Rahman M, Wahl P, Amaral AP, Hamano T, Master SR, Nessel L, Chai B, Xie D, Kallem RR, Chen J, Lash JP, Kusek JW, Budoff MJ, Giachelli CM, Wolf M: Chronic Renal Insufficiency Cohort Study I: Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int 2013; 83: 1159-1168.
48. Xie J, Cha SK, An SW, Kuro OM, Birnbaumer L, Huang CL: Cardioprotection by klotho through downregulation of TRPC6 channels in the mouse heart. Nat Commun 2012; 3: 1238.
49. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro OM, Kusek JW, Keane MG, Wolf M: FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408.
50. McGraw AP, McCurley A, Preston IR, Jaffe IZ: Mineralocorticoid receptors in vascular disease: connecting molecular pathways to clinical implications. Curr Atheroscler Rep 2013; 15: 340.
51. Jaffe IZ, Tintut Y, Newfell BG, Demer LL, Mendelsohn ME: Mineralocorticoid receptor activation promotes vascular cell calcification. Arterioscler. Thromb Vasc Biol 2007; 27: 799-805.
52. Wu SY, Yu YR, Cai Y, Jia LX, Wang X, Xiao CS, Tang CS, Qi YF: Endogenous aldosterone is involved in vascular calcification in rat. Exp Biol Med (Maywood) 2012; 237: 31-37.
53. Jaffe IZ, Mendelsohn ME: Angiotensin II and aldosterone regulate gene transcription via functional mineralocorticoid receptors in human coronary artery smooth muscle cells. Circ Res 2005; 96: 643-650.
54. Newfell BG, Iyer LK, Mohammad NN, Mc-Graw AP, Ehsan A, Rosano G, Huang PL, Mendelsohn ME, Jaffe IZ: Aldosterone regulates vascular gene transcription via oxidative stress-dependent and-independent pathways. Arterioscler Thromb Vasc Biol 2011; 31: 1871-1880.
55. Cooper JN, Tepper P, Barinas-Mitchell E, Woodard GA, Sutton-Tyrrell K: Serum aldosterone is associated with inflammation and aortic stiffness in normotensive overweight and obese young adults. Clin Exp Hypertens 2012; 34: 63-70.
56. De Rita O, Hackam DG, Spence JD: Effects of aldosterone on human atherosclerosis: plasma aldosterone and progression of carotid plaque. Can J Cardiol 2012; 28: 706-711.
57. Hillaert MA, Lentjes EG, Kemperman H, van der GY, Nathoe HM, Beygui F, Montalescot G, Doevendans PA, Wassink AM, van Belle E: Aldosterone, atherosclerosis and vascular events in patients with stable coronary artery disease. Int J Cardiol 2012; 167: 1929-1935.
58. Suzuki J, Iwai M, Mogi M, Oshita A, Yoshii T, Higaki J, Horiuchi M: Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 2006; 26: 917-921.
59. Galmiche G, Pizard A, Gueret A, El Moghrabi S, Ouvrard-Pascaud A, Berger S, Challande P, Jaffe IZ, Labat C, Lacolley P, Jaisser F: Smooth muscle cell mineralocorticoid receptors are mandatory for aldosterone-salt to induce vascular stiffness. Hypertension 2014; 63: 520-526.
60. Quaschning T, Ruschitzka F, Shaw S, Luscher TF: Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. Hypertension 2001; 37: 801-805.
61. Rickard AJ, Morgan J, Chrissobolis S, Miller AA, Sobey CG, Young MJ: Endothelial cell mineralocorticoid receptors regulate deoxycorticosterone/salt-mediated cardiac remodeling and vascular reactivity but not blood pressure. Hypertension 2014; 63: 1033-1040.
62. Lang F: Stiff endothelial cell syndrome in vascular inflammation and mineralocorticoid excess. Hypertension 2011; 57: 146-147.
63. Oberleithner H: Aldosterone makes human endothelium stiff and vulnerable. Kidney Int 2005; 67: 1680-1682.
64. Druppel V, Kusche-Vihrog K, Grossmann C, Gekle M, Kasprzak B, Brand E, Pavenstadt H, Oberleithner H, Kliche K: Long-term application of the aldosterone antagonist spironolactone prevents stiff endothelial cell syndrome. FASEB J 2013; 27: 3652-3659.
65. Lang F, Bohmer C, Palmada M, Seebohm G, Strutz-Seebohm N, Vallon V: (Patho)physiological significance of the serum-and glucocorticoid-inducible kinase isoforms. Physiol Rev 2006; 86: 1151-1178.
66. Shroff R: Phosphate is a vascular toxin. Pediatr Nephrol 2012; 28: 583-593.
67. Koleganova N, Piecha G, Ritz E, Schirmacher P, Muller A, Meyer HP, Gross ML: Arterial calcification in patients with chronic kidney disease. Nephrol Dial Transplant 2009; 24: 2488-2496.
68. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H: Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740.
69. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G: Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005; 112: 2627-2633.
70. Bomback AS, Klemmer PJ: Mineralocorticoid receptor blockade in chronic kidney disease. Blood Purif 2012; 33: 119-124.
71. Hene RJ, Boer P, Koomans HA, Mees EJ: Plasma aldosterone concentrations in chronic renal disease. Kidney Int 1982; 21: 98-101.
72. Allen LA, Shetterly SM, Peterson PN, Gurwitz JH, Smith DH, Brand DW, Fairclough DL, Rumsfeld JS, Masoudi FA, Magid DJ: Guideline concordance of testing for hyperkalemia and kidney dysfunction during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure. Circ Heart Fail 2014; 7: 43-50.
73. Bae EH, Kim IJ, Joo SY, Kim EY, Kim CS, Choi JS, Ma SK, Kim SH, Lee JU, Kim SW: Renoprotective effects of sildenafil in DOCAsalt hypertensive rats. Kidney Blood Press Res 2012; 36: 248-257.
74. Baker WL, White WB: Safety of mineralocorticoid receptor antagonists in patients receiving hemodialysis. Ann Pharmacother 2012; 46: 889-894.
75. Bienvenu LA, Reichelt ME, Delbridge LM, Young MJ: Mineralocorticoid receptors and the heart, multiple cell types and multiple mechanisms: a focus on the cardiomyocyte. Clin Sci (Lond) 2013; 125: 409-421.
76. Bomback AS, Klemmer PJ: Mineralocorticoid receptor blockade in chronic kidney disease. Blood Purif 2012b;33: 119-124.
77. Chen H, Sun F, Zhong X, Shao Y, Yoshimura A, Liu Y: Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress. Kidney Blood Press Res 2013; 37: 557-566.
78. Collin M, Niemann F, Jaisser F: Mineralocorticoid receptor modulators: a patent review (2007-2012). Expert Opin Ther Pat 2014; 24: 177-183.
79. Funder JW: Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine. Integr Blood Press Control 2013; 6: 129-138.
80. Hammer F, Krane V, Stork S, Roser C, Hofmann K, Pollak N, Allolio B, Wanner C: Rationale and design of the Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Study (MiREnDa). Nephrol Dial Transplant 2014; 29: 400-405.
81. Lahmer T, Hermans R, Schmaderer C, Chang J, Stock K, Lutz J, Heemann U, Baumann M: Mineralocorticoid receptor antagonism and aldosterone synthesis inhibition do not improve glomerulosclerosis and renal interstitial fibrosis in a model of chronic kidney allograft injury. Kidney Blood Press Res 2012; 35: 561-567.
82. Makowka A, Olejniczak-Fortak M, Nowicki M: A comparison of the antihypertensive and anti-inflammatory effects of aliskiren and ramipril add-on therapy in peritoneal dialysis patients-a pilot open label study. Kidney Blood Press Res 2012; 36: 18-25.
83. Markowitz M, Messineo F, Coplan NL: Aldosterone receptor antagonists in cardiovascular disease: a review of the recent literature and insight into potential future indications. Clin Cardiol 2012; 35: 605-609.
84. Mavrakanas TA, Gariani K, Martin PY: Mineralocorticoid receptor blockade in addition to angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review. Eur J Intern Med 2014; 25: 173-176.
85. Piotrowski DW: Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy. J Med Chem 2012; 55: 7957-7966.
86. Pitt B: The role of mineralocorticoid receptor antagonists in patients with American College of Cardiology/American Heart Association stage B heart failure. Heart Fail Clin 2012; 8: 247-253.
87. Richards AM: Mineralocorticoid receptor antagonists for heart failure. Expert Opin Pharmacother 2011; 12: 2801-2815.
88. Ronconi V, Turchi F, Appolloni G, di Tizio V, Boscaro M, Giacchetti G: Aldosterone, mineralocorticoid receptor and the metabolic syndrome: role of the mineralocorticoid receptor antagonists. Curr Vasc Pharmacol 2012; 10: 238-246.
89. Roscioni SS, de Zeeuw D, Bakker SJ, Lambers Heerspink HJ: Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy. Nat Rev Nephrol 2012; 8: 691-699.
90. Sato A: Mineralocorticoid receptor antagonists: their use and differentiation in Japan. Hypertens Res 2013; 36: 185-190.
91. Seawell MR, Al Darazi F, Farah V, Ramanathan KB, Newman KP, Bhattacharya SK, Weber KT: Mineralocorticoid receptor antagonism confers cardioprotection in heart failure. Curr Heart Fail Rep 2013; 10: 36-45.
92. Shavit L, Lifschitz MD, Epstein M: Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms. Kidney Int 2012; 81: 955-968.
93. Talatinian A, Chow SL, Heywood JT: Expanding role of mineralocorticoid receptor antagonists in the treatment of heart failure. Pharmacotherapy 2012; 32: 827-837.
94. Tylicki L, Lizakowski S, Rutkowski P, Renke M, Sulikowska B, Heleniak Z, Donderski R, Bednarski R, Przybylska M, Manitius J, Rutkowski B: The enhanced renin-angiotensinaldosterone system pharmacological blockade-which is the best? Kidney Blood Press Res 2012; 36: 335-343.
95. Van den Berg TN, Rongen GA, Frohlich GM, Deinum J, Hausenloy DJ, Riksen NP: The cardioprotective effects of mineralocorticoid receptor antagonists. Pharmacol Ther 2014; 142: 72-87.
96. Young MJ: Targeting the mineralocorticoid receptor in cardiovascular disease. Expert Opin Ther Targets 2013; 17: 321-331.
97. Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJ, Swedberg K, Struthers AD, Voors AA, Ruilope LM, Bakris GL, O'Connor CM, Gheorghiade M, Mentz RJ, Cohen-Solal A, Maggioni AP, Beygui F, Filippatos GS, Massy ZA, Pathak A, Pina IL, Sabbah HN, Sica DA, Tavazzi L, Pitt B: Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J 2012; 33: 2782-2795.
98. Zwadlo C, Bauersachs J: Mineralocorticoid receptor antagonists for therapy of coronary artery disease and related complications. Curr Opin Pharmacol 2013; 13: 280-286.
99. Ito Y, Mizuno M, Suzuki Y, Tamai H, Hiramatsu T, Ohashi H, Ito I, Kasuga H, Horie M, Maruyama S, Yuzawa Y, Matsubara T, Matsuo S, Nagoya Spiro Study Group: Long-term effects of spironolactone in peritoneal dialysis patients. J Am Soc Nephrol 2014; 25: 1094-1102.
100. Flevari P, Kalogeropoulou S, Drakou A, Leftheriotis D, Panou F, Lekakis J, Kremastinos D, Vlahakos DV: Spironolactone improves endothelial and cardiac autonomic function in non-heart failure hemodialysis patients. J Hypertens 2013; 31: 1239-1244.
101. Matsumoto Y, Mori Y, Kageyama S, Arihara K, Sugiyama T, Ohmura H, Yakushigawa T, Sugiyama H, Shimada Y, Nojima Y, Shio N: Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol 2014; 63: 528-536.
102. Edwards NC, Steeds RP, Chue CD, Stewart PM, Ferro CJ, Townend JN: The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. Br J Clin Pharmacol 2012; 73: 447-454.
103. Bianchi S, Bigazzi R, Campese VM: Longterm effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006; 70: 2116-2123.